Skip to main content
. Author manuscript; available in PMC: 2013 Sep 20.
Published in final edited form as: Stroke. 2011 Jul 21;42(9):2672–2713. doi: 10.1161/STR.0b013e3182299496

Table 3.

Pharmacological Treatments for VCI

Treatment Recommendation (Class/Level of Evidence) Comments
Donepezil396–400 Class IIa, Level A, for “pure” VaD Study 307, 308 (n=1219): modest benefit for cognitive and global, less robust for function; Study 319 (n= 974): only cognitive benefit
Galantamine401–403 Class IIa, Level A, for mixed Alzheimer disease–cerebrovascular disease; Class IIb for “pure” VaD Pure and mixed VaD Gal-Int-6 (n=592): benefit in all primary outcomes overall; only cognitive benefit in pure disease; “Pure” VaD (Gal-Int-26; n= 788): modest benefit in cognitive/executive measures
Rivastigmine404,405 Class IIb, Level C VCIND study (n=50): modest benefit in some executive functions
Memantine406,407 Class IIb, Level A n= 900: Modest cognitive benefits only

VCI indicates vascular cognitive impairment; VaD, vascular dementia; and VCIND, vascular cognitive impairment, no dementia. Study 307, 308, and 319 and “Gal-Int-6” and “Gal-Int-26” are names of the studies.